Neurofibromatosis Type 1 in a Pediatric Population: Ste-Justine's Experience

Canadian Journal of Neurological Sciences - Tập 32 Số 2 - Trang 225-231 - 2005
Jean-Martin Boulanger1, Albert Larbrisseau1
1Division of Pediatric Neurology HSJ, Department of Pediatrics, Montreal University, Montreal, QC, Canada

Tóm tắt

ABSTRACT:Background:

To date, few pediatric series of neurofibromatosis type 1 (NF-1) have been described in the literature even though it is the most frequently encountered phakomatosis.

Methods:

We reviewed 987 charts of pediatric patients with a presumptive diagnosis of NF-1 who were evaluated at Ste-Justine hospital from January 1, 1991 to July 31, 2002. Patients who presented with two or more cardinal criteria were diagnosed with NF-1. Clinical and laboratory data were retrospectively collected, including: demographics, neuroimaging and presence or absence of associated symptoms or signs of NF-1.

Results:

A total of 279 patients were diagnosed with NF-1. The mean age at diagnosis was 3.4 years. Ninety-nine percent of the patients had café au lait spots and 47% had a first degree relative with NF-1. Almost 60 percent (59.6%) of those seen by an ophthalmologist had Lisch nodules. Optic glioma was found in in 14.7%, cutaneous neurofibromas in 38.4%, plexiform neurofibromas in 24.7%, neurofibrosarcoma in 1.8%, learning disabilities in 39%, attention deficit disorder in 40.5%, osseous dysplasias in 7.2%, pseudoarthrosis in 3.6%, precocious puberty in 3.2% and short stature in 17.9%. Magnetic resonance, when performed, showed hyperintense T2 lesions in 87.1% of cases. The mean period of follow-up was 7.4 years.

Conclusion:

Neurofibromatosis type 1 is a multisystemic disorder associated with increased risk of malignancy. It can be diagnosed at a very young age and clinical follow-up is advised. To our knowledge, this is the largest single center study of NF-1 in a pediatric population.

Từ khóa


Tài liệu tham khảo

10.1016/S0887-8994(98)00075-7

10.1007/s004679900260

10.1212/WNL.48.4.1121

10.1212/WNL.46.6.1660

10.1136/jnnp.59.6.638

10.1212/01.WNL.0000055090.78351.C1

10.1212/01.WNL.0000098881.95854.5F

10.1212/WNL.44.5.878

10.1038/nature711

10.1076/chin.6.3.185.3155

McCarron, 1998, Plexiform neurofibroma with andwithout associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases, Mod Pathol, 11, 612

10.1016/S0022-3476(97)70092-1

10.1515/JPEM.2000.13.S1.841

10.1542/peds.100.4.667

10.1016/S0929-693X(01)00991-5

10.1016/S0022-3476(94)70122-9

10.1136/adc.78.5.408

1987, neurofibromatosis

10.1002/(SICI)1096-8628(19990326)89:1<14::AID-AJMG5>3.0.CO;2-4

10.1126/science.3107130

10.1542/peds.105.3.608

10.1001/archopht.119.4.516

10.1136/adc.87.1.65

Es, 1996, MRI findings in children with neurofibromatosis type 1: a prospective study, PediatrRadiol, 26, 478

Huson, 1994, The Neurofibromatoses: A Pathogenetic and Clinical Overview, 160

Virdis, 1994, Hypertension in childrenwith neurofibromatosis, J Hum Hypertens, 8, 395

10.1016/S0002-9394(00)00852-7

10.1136/jmg.26.11.712

10.1016/0092-8674(90)90150-D

10.1001/archneur.55.6.778

Obringer, 1989, The diagnosis of neurofibromatosis-1 in the child under the age of 6 years, Am J Dis Child, 143, 717